Recently, it was proven that tectorigenin targeted protein kinase A catalytic subunit α (PKACα) to promote the PKA/AMPK/myocyte enhancer factor 2 (MEF2) pathway, subsequently enhancing GLUT4 expression, and thus slowing and stopping insulin resistance progression for the intervention and treatment of glucose metabolism syndrome [99]. This evidence concerns the gene PRKACA and Insulin resistance.